Bionano Genomics reports Q3 2022 revenue of $7.2M, up 55% YoY; guides Q4 $7.5-8M

Bionano Genomics, Inc.

2022-Q3 EPS reported -$0.33 revenue$19,587,000

Revenue $7.2M, up 55% YoY and 8% sequentially; gross margin 25%, up 3% sequentially.
Installed base of Saphyr systems increased to 217, up 11% sequentially and 54% YoY; record flowcell sales of 3,975.
GAAP operating expense $34.0M; non-GAAP $26.4M; cash $180.2M.
Q4 2022 revenue guidance $7.5M to $8M.
Bionano Laboratories received CLIA certification; launched first OGM-based LDT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Bionano Genomics, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022 , Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-22-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.